Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement. Veeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro. Ostro has developed an artificial intelligence-based chat tool for pharmas that provides patients and clinicians with drug information drawn only from approved materials compliant with medical, legal and regulatory requirements. Ostro's chat tool can be integrated into drug brands' websites, emails and text messages, where it answers direct questions from consumers and points to relevant resources. From there, it analyzes the interactions to give pharma clients data-backed tips for boosting engagement. According to the company, its AI platform is used by "most" of the 20 biggest global pharmas, including the likes of Johnson & Johnson, Eli Lilly, AstraZeneca and Sanofi. Veeva is paying approximately $100 million to acquire Ostro, according to this week's announcement, comprising a combination of cash and long-term equity retention grants. Post-acquisition, Ostro will continue to operate as an independent unit under the Veeva umbrella, still led by CEO Chase Feiger, M.D. Eventually, per the announcement, the companies plan to "develop integrations" between Ostro's technology and Veeva's cloud-based software programs, with the aim of improving customer-centricity by connecting online and in-the-field interactions with patients and doctors. "We're focused on shortening the time it takes to identify and treat health conditions," Feiger said in the release. "Brand content should be effortless to access and fully compliant by design. We built Ostro to remove friction so patients and doctors can get trusted answers with less clicking, thinking, and scrolling. With Veeva, we can bring that experience to many more patients, doctors, and brands." Let Google know we are your trusted source. Add our editorial as a preferred source in your search results.

Veeva acquires Ostro, the leading brand engagement platform for life sciences. Mar 10, 2026, 11:45 ET PLEASANTON, Calif., March 10, 2026 /PRNewswire/ - Veeva Systems (NYSE: VEEV) today announced the acquisition of Ostro, the leading brand engagement platform for life sciences that gives patients and doctors immediate, compliant answers through an easy-to-use AI-driven chat experience. Ostro-powered brand websites allow customers to easily ask questions and receive approved information, resources, and next steps in real-time. Leveraging this rich engagement data, Ostro also generates deep insights brands use to improve reach and engagement. Ostro utilizes a combination of conversational AI, semantic search, and industry-specific business rules and guardrails. Responses are 100% compliant and drawn from MLR-approved materials. Unlike other AI solutions, Ostro does not hallucinate or generate novel responses. "AI has changed how people get information. It's no longer about how much information you can put out there, it's about how easy it is for customers to get answers," said Veeva CEO Peter Gassner. "Ostro is leading the way in helping brands ensure patients and doctors have instant access to accurate information. We're excited to welcome Ostro to the Veeva team as we shape the future of AI-powered customer engagement." "We're focused on shortening the time it takes to identify and treat health conditions," said Chase Feiger, MD, CEO of Ostro. "Brand content should be effortless to access and fully compliant by design. We built Ostro to remove friction so patients and doctors can get trusted answers with less clicking, thinking, and scrolling. With Veeva, we can bring that experience to many more patients, doctors, and brands." Veeva acquired Ostro for a purchase price of approximately $100 million in cash and long-term equity retention grants. Ostro will operate as an independent unit led by CEO Chase Feiger. Over time, the company will develop integrations between Ostro and Veeva Commercial Cloud applications for seamless workflows that connect online and field engagements for greater customer centricity. Learn more at ostro.veeva.com. About Veeva Systems Veeva delivers the industry cloud for life sciences with software, data, and business consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-Looking Statements This release contains forward-looking statements about the expected results and benefits from our acquisition of Ostro. These statements are based on our current plans, estimates, and expectations. Acquisitions are risky, and we cannot be certain of success. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. We describe the risks and uncertainties that we believe are most relevant to our business, including risks associated with acquisitions, in our periodic reports with the SEC available at ir.veeva.com and at sec.gov.